The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study Comparative Study
Fibrinolysis for patients with intermediate-risk pulmonary embolism.
The role of fibrinolytic therapy in patients with intermediate-risk pulmonary embolism is controversial. ⋯ In patients with intermediate-risk pulmonary embolism, fibrinolytic therapy prevented hemodynamic decompensation but increased the risk of major hemorrhage and stroke. (Funded by the Programme Hospitalier de Recherche Clinique in France and others; PEITHO EudraCT number, 2006-005328-18; ClinicalTrials.gov number, NCT00639743.).